source
- Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipelineVedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…
- FDA approves OTC naloxone nasal spray Rextovy, expanding consumer access to overdose treatmentThe FDA announced approval of a new over-the-counter naloxone nasal spray called Rextovy, delivering 4 mg of naloxone hydrochloride for emergency reversal of opioid overdose. The product can be pu…